Adult astrocytic tumor

Summary

Adult astrocytic tumor (MONDO:0002503) is a cancer and 4 clinical trials. Top therapeutic interventions include cabozantinib and tarlatamab. A subtype of astrocytic tumor — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Clinical trials: 4

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	adult astrocytic tumor
Mondo ID	MONDO:0002503
DOID	DOID:3076
NCIT	C7049
UMLS	C1332183
MedGen	272290
GARD	0023151
Is cancer (heuristic)	yes

Also known as: adult astrocytic neoplasm · adult astrocytic tumor · astrocytic tumor · astrocytic tumour

Disease family

This is a subtype of astrocytic tumor. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › nervous system neoplasm › neuroepithelial neoplasm › glioma › astrocytic tumor › adult astrocytic tumor

Related subtypes (7): childhood astrocytic tumor, gliofibroma, high grade astrocytic tumor, astrocytoma (excluding glioblastoma), low grade astrocytic tumor, anaplastic pleomorphic xanthoastrocytoma, infant-type hemispheric glioma

Subtypes (2): adult brainstem astrocytoma, adult infiltrating astrocytic neoplasm

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 4.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	2
PHASE1	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06776250	PHASE2	RECRUITING	Study of How Safe and Effective Tarlatamab is in Brain Cancers
NCT01068782	PHASE2	TERMINATED	Multiple Doses and Regimens of Cabozantinib in Subjects With Grade IV Astrocytic Tumors in First or Second Relapse
NCT01967758	PHASE1	COMPLETED	Phase I Study of Safety and Immunogenicity of ADU-623
NCT06620926	Not specified	COMPLETED	Impact of IDH Mutation and Adjuvant Chemo(radio)therapy on Survival Outcome in Grade II/III Astrocytoma

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
CABOZANTINIB	4	1
TARLATAMAB	4	1
CHEMBL4215501	0	1
CHEMBL4849721	0	1
EXELIXIS	0	1